KR101613056B1 - Prophylactic and therapeutic materials for metabolic syndrome with the extracts of citrus unshiu peel and paullinia cupana - Google Patents

Abstract

The present invention relates to a composition for preventing, ameliorating or treating metabolic syndrome, which comprises a dermis and a guarana extract as an active ingredient.
The present invention is characterized in that the weight ratio of dermis to guarana is 0: 500 to 500: 0.
The present invention relates to the use of the extracts for the treatment of obesity, hyperlipidemia, hyperlipidemia, hyperlipidemia, hyperlipidemia, hyperlipidemia, hyperlipidemia, hyperlipidemia, hyperlipidemia, hyperlipidemia, hyperlipidemia, And efficacy to reduce LDL cholesterol, efficacy to reduce arteriosclerosis index, efficacy to reduce cardiac risk index, efficacy to reduce blood sugar and liver fat accumulation, efficacy to reduce liver inflammation, decrease liver balloon count And the ability to reduce the size of fat cells.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention, improvement or treatment of metabolic syndrome which contains dermis and guarana as an active ingredient. BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for preventing,

The present invention relates to a composition for preventing, ameliorating or treating metabolic syndrome, which comprises a dermis and a guarana extract as an active ingredient.

The composition according to the present invention is characterized in that the weight ratio of dermis to guarana is 0: 500 to 500: 0.

The composition according to the present invention is characterized in that it is orally administered at 450 to 550 mg / kg once a day on the basis of a 5-week-old mouse.

The composition according to the present invention is useful for reducing body weight, reducing liver weight, reducing fat weight, inhibiting liver damage, reducing neutral lipid and total cholesterol, and enhancing HDL cholesterol And efficacy to reduce LDL cholesterol, efficacy to reduce arteriosclerosis index, efficacy to reduce cardiac risk index, efficacy to reduce blood sugar and liver fat accumulation, efficacy to reduce liver inflammation, decrease liver balloon count And the ability to reduce the size of fat cells.

Diabetes, impaired glucose tolerance, obesity, hypertension, hyperlipidemia, heart disease, stroke, and atherosclerosis are diseases in which various cardiovascular risk factors are expressed in a cluster in a cluster and are related to each other . For example, the risk of cardiovascular disease associated with metabolic syndrome is amplified at the onset of diabetes. These are diseases that are intertwined mutually organically. Recently, they are recognized as diverse diseases such as diabetes, impaired glucose tolerance, obesity, hypertension, atherosclerosis, hyperlipidemia, heart disease and stroke. The term metabolic syndrome is a concept that encompasses these diseases.

The incidence of metabolic syndrome was investigated based on the data of National Health and Nutrition Survey conducted in 1998 and 2001.

The prevalence of age-adjusted metabolic syndrome increased from 22.5% in 1998 to 24.1% in 2001, an increase of 7.1% over the past three years, according to an analysis of the increasing pattern of metabolic syndrome in Koreans. According to the National Nutrition Health Survey 2005 by the research team of Professor Kim Hyun-Chang of the Department of Preventive Medicine, Yonsei University College of Medicine, more than 50% of Koreans over 60 have metabolic syndrome prevalence.

Recently, the incidence of metabolic syndrome in the 30s, a young group, has been greatly increased. In the Annals of Epidemiology published by the American Epidemiology Society, a team of Professor Yoo Seung-Ho of the Department of Occupational Medicine at Kangbuk Samsung Hospital conducted a survey of 4,779 people in their 30s who had no metabolic syndrome in 2002 14.8% (708) were diagnosed with a new metabolic syndrome a month after a month. Thus, metabolic syndrome is a disease that can develop regardless of factors, and it is emerging as an important issue in socioeconomic environment.

Examples of the treatment of metabolic syndrome include weight loss drugs, PPAR agonists, beta-3 receptor agonists, alpha-lipoic acid, hypoglycemic agents, hypotensive agents, and the like.

Representative diseases of metabolic syndrome include dyslipidemia and obesity, and the diseases will be briefly described below

On the other hand, lipid is a concept that includes cholesterol and triglycerides. There are many types of lipids, often called lipoproteins. Common lipid tests include total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglycerides.

LDL cholesterol is known as 'bad cholesterol' and high LDL cholesterol levels increase the risk of heart attack and stroke. HDL cholesterol is known as 'good cholesterol' and high HDL cholesterol levels reduce the risk of heart attack or stroke. Triglyceride is a type of lipid that is different from cholesterol, and high triglyceride levels increase the risk of heart attack or stroke. The diseases such as increased total cholesterol, LDL cholesterol, triglyceride or decreased HDL cholesterol are referred to as hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and the like. Usually, dyslipidemia is a disease name which includes the above diseases.

The causes of dyslipidemia can be classified into congenital and acquired factors. Congenital factors are genetic factors, which cause abnormal lipidemia by increasing specific lipid in the blood due to genetic abnormality. Acquired factor is the cause of hyperlipemia due to factors such as obesity.

Diagnosis of dyslipidemia is diagnosed as abnormal dyslipidemia when an abnormality is found in one or more items when the following items are measured more than once. (Total cholesterol less than 200 mg / dL, LDL cholesterol less than 130 mg / dL, HDL cholesterol less than 60 mg / dL, and triglycerides less than 150 mg / dL)

These criteria are intended for people who do not have risk factors such as heart disease and stroke, and the normal range of people with risk factors may vary.

The treatment of hyperlipidemia includes the use of drugs such as statin, fibrate, nicotinic acid, ezetimibe, omega-3 fatty acid alone or in combination .

However, each drug has side effects. Table 2 below shows the side effects of each drug.

Drug name Side Effect Statin Hepatotoxicity, myopathy Fibrates Gallstone, myopathy Nicotinic acid Skin redness, digestive disorders, hepatotoxicity, gout, increased blood sugar Ezetimibe Increased intestinal gas, constipation Omega-3 fatty acids Fishy smell, skin rash

On the other hand, obesity refers to a state in which unheated calories are accumulated excessively in the body because the calories consumed are higher than the calories consumed. The concept of numerical value is defined as obesity when the body mass index (BMI) is 25 or more. The BMI method is an obesity measurement method that estimates the amount of body fat by dividing the body weight (kg) by the square of the height (㎡).

The causes of obesity can be classified into genetic factors and lifestyle factors. Genetic factors include obesity genes such as FTO. Over 20 genes have been identified so far, among which FTO is a representative obesity gene. FTO is involved in regulating the satiety of the hypothalamus, and it is known to inhibit the secretion of hormones that can feel satiety.

Lifestyle factors include lack of exercise and unbalanced eating habits. If the exercise is insufficient, the body fat accumulates without burning. In addition, if the nutrients are not balanced, such as excessive intake of carbohydrates and fats and low intake of vitamins and fibers, the fat in the body accumulates without burning, as in the case of lack of exercise.

Treatment of obesity includes medication. Drug therapy is a treatment for obesity patients to treat obesity, the treatment of obesity will be briefly.

Types of obesity treatments include appetite suppressants, metabolism inhibitors, absorption inhibitors, and heat production promoters. An appetite suppressant is also called a satiety-suppressing agent. It acts on the satiety-lowering center of the hypothalamus and produces a similar effect to that consumed by a small amount of food. Fendimetrazine, pentamine, and the like.

Metabolic agonists increase energy expenditure in the body and increase basal metabolism.

Absorption inhibitors inhibit the action of gastrointestinal fat-degrading enzymes and inhibit fat absorption. Heat production promoters can be supplemented with appetite suppressants, which can maximize the effects of appetite suppressants.

However, all of the obesity treatment drugs have side effects. Table 2 below shows the side effects of each drug.

Types of Obesity Remedy Side Effect Appetite suppressant (satiety stimulant) Headache, insomnia, etc. Metabolism stimulant Hands and feet Absorption inhibitor Feces, frequent farts, etc. Heat Generation Accelerator Hand shake etc.

Therefore, the Applicant has found a composition which can prevent, ameliorate or treat metabolic syndrome by effectively reducing the lipid in plasma without using side effects by utilizing a substance derived from natural origin.

The present invention uses dermis and guarana as a natural material, and a description will now be given of a natural material used as a material of the present invention.

The dermis (Citri Pericarpium) belongs to the genus Citrus ( Citrus unshiu Marko.) is the shell.

The dermis contains 1.5 to 2% of essential oil and contains limonene, bioflavonoid, isopropenyl, toluene, 8-elemene, d-copaene, , alpha-humulene, vitamin B and C, and the like.

Among the ingredients of the dermis, especially pharmacologically active ingredients are known as bioflavonoids. About 60 kinds of bioflavonoids have been isolated and their structure has been revealed. Over 90% of them are known as hesperidin and naringin.

Figure 1 is a table showing the chemical structure of Naringin.

The dermis is effective to treat symptoms such as trimming, vomiting, nausea, indigestion, flatulence, sperm, seawater and sputum, and has diuretic effects.

The guarana ( Paullinia cupana HBK) is a vine plant belonging to the moth family.

The guarana contains ingredients such as heobromine, theophylline, caffeine, adenine and xanthine.

Caffeine, a component of guarana, does not stimulate nerves unlike caffeine contained in coffee or green tea, and the content of caffeine in guarana is about twice the amount of caffeine in coffee.

Figure 2 is a table showing the chemical structure of caffeine.

Guarana has the ability to treat symptoms such as constipation, diarrhea, indigestion, gastrointestinal gas, and neuralgia. It also has antimicrobial, anti-aging, anti-aging, elimination of body waste, diuretic, relieving stress and improving concentration.

In the prior art for metabolic syndrome based on dermis or guarana, Korean Patent Registration No. 10-0826863 discloses a green tea extract containing epigallocatechin gallate (EGCG), a cholera toxoid extract, Alba extract and guarana or Yerbamate extract as active ingredients, and Korean Patent Publication No. 10-2011-0098271 discloses a composition comprising a compound of formula (I), a compound of formula (I), a compound of formula , Omega, aloe avoresense powder, guarana extract powder, soybean protein peptide powder, grain enzyme powder and grapefruit seed extract as effective ingredients.

Korean Patent Laid-Open Publication No. 10-2008-0039874 discloses a composition containing an extract of Evodiae Fructus, Imperatae Rhizoma and Citrus Unshiu Markovich as an active ingredient.

However, in the above-mentioned prior arts, only the experiment focused mainly on obesity, such as weight change, body fat reduction, and triglyceride reduction, was performed in the 10-0826863, and 10-2011-0143224 also focused on obesity such as weight change It can be seen that the experiment was performed only.

10-2008-0039874 discloses that an experiment focused on obesity or diabetes, such as an experiment of AMPKa activity inhibition and the like, and a comparative experiment with troglitazone, which is a diabetic therapeutic agent, has been performed. In the above- In the experiment.

In addition, the above-mentioned prior art documents only the efficacy of using dermis and guarana in combination with other materials, and does not mention the efficacy of the combination of dermis and guarana. .

Korean Registered Patent No. 10-0826863 (Apr. 25, 2008) Korean Patent Publication No. 10-2011-0143224 (Apr. 31, 2013) Korean Patent Publication No. 10-2008-0039874 (2009.11.03)

It is an object of the present invention to provide a composition for prevention, improvement or treatment of metabolic syndrome containing dermis and guarana extract as an active ingredient.

It is an object of the present invention to provide a composition for prevention, improvement or treatment of metabolic syndrome wherein the weight ratio of dermis to guarana is 0: 500 to 500: 0.

The object of the present invention is to provide a composition for the prevention, improvement or treatment of metabolic syndrome, which is characterized in that 450 to 550 mg / kg orally is administered once a day on a 5-week-old mouse basis

It is an object of the present invention to provide a method of reducing weight loss, an effect of reducing liver weight, an effect of decreasing fat weight, an effect of inhibiting liver damage, an effect of decreasing triglyceride and total cholesterol, an effect of increasing HDL cholesterol, Efficacy to reduce LDL cholesterol, efficacy to reduce atherosclerosis index, efficacy to reduce cardiac risk index, efficacy to reduce blood sugar and liver fat accumulation, efficacy to reduce liver inflammation, Efficacy, and the ability to reduce the size of adipocytes, and to provide a composition for preventing, ameliorating, or treating metabolic syndrome.

In order to achieve the above object, the present invention aims to solve the technical problem by providing a composition for prevention, improvement or treatment of metabolic syndrome containing the dermis and guarana extract as an active ingredient.

The present invention aims at solving the technical problem by providing a composition for prevention, improvement or treatment of metabolic syndrome wherein the weight ratio of dermis to guarana is 0: 500 to 500: 0.

The present invention provides a composition for preventing, ameliorating or treating metabolic syndrome, which is characterized by being orally administered once a day at 450 to 550 mg / kg on the basis of a 5-week-old mouse.

The present invention provides a method of reducing weight loss, an effect of decreasing liver weight, an effect of decreasing fat weight, an effect of inhibiting liver damage, an effect of decreasing neutral lipid and total cholesterol, an effect of increasing HDL cholesterol, Efficacy to reduce atherosclerosis index, efficacy to reduce cardiac risk index, efficacy to reduce blood sugar and efficacy to decrease liver fat accumulation, efficacy to decrease liver inflammation, It is intended to solve the technical problem by providing a composition for the prevention, improvement or treatment of metabolic syndrome which has an effect of reducing the size of adipocytes.

The composition for prevention, improvement or treatment of metabolic syndrome containing the dermis and guarana extract according to the present invention as an active ingredient has an efficacy without side effects and cytotoxicity.

The composition for prevention, improvement or treatment of metabolic syndrome comprising the dermis and guarana extract according to the present invention as an active ingredient can be used for reducing weight loss, reducing liver weight, reducing fat weight, inhibiting liver damage ≪ / RTI > efficacy, neutral lipid and total cholesterol.

The composition for preventing, ameliorating or treating metabolic syndrome comprising the dermis and guarana extract according to the present invention as an active ingredient is a composition for improving HDL cholesterol and reducing LDL cholesterol, an effect for reducing arteriosclerosis index, It has an efficacy to reduce the index.

The composition for prevention, improvement or treatment of metabolic syndrome containing the dermis and scallop extract according to the present invention as an active ingredient is useful for reducing blood sugar, reducing liver fat accumulation, reducing liver inflammation, ≪ / RTI > and the ability to reduce the size of fat cells.

Figure 1 is a table showing the chemical structure of Naringin.
Figure 2 is a table showing the chemical structure of caffeine.
3 is a table showing final compound information of Naringin.
Figures 4, 5, 6, 7, 8, 9, and 10 are graphs of analytical chemical analysis of Naringin.
11 is a graph comparing the chromatography of caffeine contained in guarana based on chromatography of 50 ppm and 100 ppm of caffeine.
12 is a graph showing a standard curve of caffeine contained in the guarana.
FIG. 13 is a table showing the dietary feeding methods of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
FIG. 14 is a table showing changes in body weight of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
15 is a graph comparing changes in body weight of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
FIG. 16 is a table comparing liver weight changes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
17 is a graph comparing the absolute liver weight changes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
18 is a graph comparing relative liver weight changes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
FIG. 19 is a table comparing the weight changes of epididymal fat, peritoneal fat, and peripheral renal fat of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
20 is a graph comparing changes in the weight of the peritoneal fat of the NC group, the HFD group, the ST group, the J100 group, the J90: G10 group, the J50: J50 group, and the G100 group.
FIG. 21 is a graph comparing changes in epididymal fat weight among NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
22 is a graph comparing the changes in the peripheral fat weight of the NC group, the HFD group, the ST group, the J100 group, the J90: G10 group, the J50: J50 group, and the G100 group.
23 is a table comparing GOT and GPT of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
24 is a table comparing the GOT of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
25 is a table comparing the GPT of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
26 is a table comparing triglyceride content and total cholesterol content of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
27 is a graph comparing triglyceride contents of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
28 is a graph comparing the total cholesterol contents of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
29 is a table comparing the HDL cholesterol and LDL cholesterol contents of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
30 is a graph comparing the HDL cholesterol contents of the NC group, the HFD group, the ST group, the J100 group, the J90: G10 group, the J50: J50 group, and the G100 group.
31 is a graph comparing the LDL cholesterol contents of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
32 is a table comparing the atherogenic indexes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
33 is a graph comparing the atherogenic indexes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
34 is a chart comparing the cardiac risk indexes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
35 is a graph comparing cardiac risk indexes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
FIG. 36 is a table comparing the blood glucose levels of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
37 is a graph comparing blood glucose levels of the NC group, the HFD group, the ST group, the J100 group, the J90: G10 group, the J50: J50 group, and the G100 group.
FIG. 38 is a table comparing NASH of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
FIG. 39 is a photograph showing anatomical comparison of the progression of NASH in NC group, HFD group, ST group, and J100 group.
40 is a photograph showing anatomical comparison of NASH progress of J90: G10 group, J50: J50 group, and G100 group.
41 is a table comparing the epididymal fat and peritoneal fat masses of the NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.
Fig. 42 is a photograph showing anatomical comparison of epididymal fat sizes of NC group (A), HFD group (B), ST group (C) and J100 group (D).
FIG. 43 is a photograph showing an epidemiological comparison of epididymal fat sizes of J90: G10 (E), J50: J50 (F) and G100 (G) groups.
FIG. 44 is a photograph showing the anatomical comparison of the peritoneal fat masses of the NC group (A), the HFD group (B), the ST group (C), and the J100 group (D).
FIG. 45 is a photograph showing the anatomical comparison of the peritoneal fat masses of J90: G10 (E), J50: J50 (F) and G100 (G) groups.

The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms and the inventor may properly define the concept of the term in order to best describe its invention It should be construed as meaning and concept consistent with the technical idea of the present invention.

Therefore, the embodiments described in the present specification, the reference examples, and the drawings are merely the most preferred examples of the present invention, and not all of the technical ideas of the present invention are described. Therefore, It should be understood that various equivalents and modifications may be present.

Example  1. Preparation of dermis and guarana extract

(1) Produce dermis and guarana extract.

Extract the dermis and guarana. Various extraction methods such as a solvent extraction method, a steam distillation method, a carbon dioxide supercritical extraction method, a steam distillation method, a microwave process extraction method, a percolation extraction method, a hot water extraction method and a fermentation extraction method can be used for the dermis and guarana extraction. . The extraction time can also be adjusted arbitrarily, and more than one extraction method can be used for the second extraction.

Extraction solvents for solvent extraction Various solvents may also be used. Extractable solvents include water, ethanol, methanol, fatty oils, glycerin, mayo, flouroprene glycol, ether, chloroform, petroleum ether, hexane, benzene, methylene chloride, ethyl acetate, acetone, butanol and isopropanol. Preferably, water may be used.

It is also possible to extract two or more solvents having different distribution coefficients at the same time, or two or more solvents can be used to extract a second or more solvent. The concentration of the extraction solvent can be adjusted depending on the type of the solvent.

The extraction time and temperature are also not limited, and can be extracted at 80 캜 for preferably 3 hours.

Preferably, the step of crushing the dermis and the guarana before the dermis and the prickly extraction is added, but the present invention is not limited thereto.

Also, the dermis and guarana may be respectively extracted and mixed, or the dermis and the guarana may be mixed and extracted.

The weight ratio of the dermis and guarana extract is based on the experimental results.

In the present invention, the effect of mixing the dermis extract and the guarana extract at a weight ratio of 0: 500, the efficacy of mixing the dermis extract and the guarana extract at a weight ratio of 1: 9, the dermis extract and the guarana extract at 1: 1, the efficacy of mixing the dermis extract and guarana extract at a weight ratio of 500: 0 was proved.

Therefore, it can be inferred that even when, for example, 50 parts by weight of the extract of guarana is mixed with 50 parts by weight of the extract of dermis, the efficacy can be exerted based on the results of the experiment.

In addition, it can be inferred that when the material extract is mixed, the weight ratio of the material extract is within the numerical range based on the experimental result, the effect can be exerted.

(2) Filter dermis and guarana extract.

There are various filtration methods such as a chromatography method and an ultrafiltration method.

(3) Concentrate the dermis and guarana extract.

The concentration method includes various methods such as freezing, concentrating under reduced pressure, concentration by evaporation, and concentration of the membrane. Preferably, the filtrate can be concentrated under reduced pressure using a rotary vacuum concentrator, but is not limited thereto.

According to the design conditions, the production examples of the dermis and guarana extract are not limited to those described above, and the order of each step may be changed flexibly.

That is, in addition to the items described above, an additional process may be performed on each material.

Example  2. Pharmaceutical preparations containing the dermis and guarana extract as active ingredients

A pharmaceutical composition for preventing, ameliorating or treating metabolic syndrome is provided by adding a pharmaceutically additive to a composition prepared by the same procedure as described in Example 1 above.

In order to use the present invention as a pharmaceutical composition, it may be prepared by a known method in the pharmaceutical field, and may be mixed with the carrier itself, a pharmaceutically acceptable carrier, excipient, diluent or the like to prepare a powder, granule, Or injections, and the like. They may also be administered orally or parenterally.

The effective dose of the composition according to the present invention can be appropriately selected according to the degree of absorption of the active ingredient in the body, the rate of water activation and excretion, the age, sex and condition of the patient, severity of the disease to be treated,

Example  3. Health functional foods containing the dermis and guarana extract as active ingredients

The present invention provides a health functional food for preventing, ameliorating or treating metabolic syndrome by adding a food additive to a composition prepared by the same process as described in Example 1 above.

The health functional food using the composition according to the present invention may be provided in various forms such as functional beverage, health supplement, tea, confectionery, and the like.

Formulations such as pills, granules, beverages, tablets, capsules and the like may be prepared using the composition according to the present invention. In this case, it is needless to say that additives may be added to prepare each formulation.

Experimental Example  1. Analysis of dermis and guarana extract

(1) Preparing the experiment

1) Experimental material

The dermis and guarana extract used extracts prepared by the same procedure as described in Example 1.

Experimental Example 1 In the following Experimental Examples, the extract prepared by the same procedure as described in Example 1 was used.

2) Reagent

Caffeine, a standard substance, was analyzed using Enzo Life Sciences (PA, USA) and Naringin (Ssigma Chemical Co, MO, USA). Extraction solvents, such as chloroform or methanol, JT Baker, NJ, USA) was used.

3) Devices

시스템(Waters ACQUITY UPLC

system (Waters Co. Ltd, MA01757, Milford, U.S.A), 워터스 제보 TQ 마스 스펙트로미터(Waters Xevo TQ mass spectrometer) (Waters Co. Ltd. Milford, MA, U.S.A), 컬럼(Waters ACQUITY UPLC BEH C

, 1.7 (2.1mm ID x 100mm L)), 센트리퓨지(centrifuge)(micro-centrifuge 1-14, Sartorius, German), 보텍스 믹서(vortex mixer)(genie-2, scientific industries, Korea), GC/MS (GC/MS-QP2010, Shimadzu, Japan), 레스텍 컬럼(Restek column (0.25 mm, 30 m; XTI-5))을 사용하였다.
The analyzers include Waters ACQUITY UPLC

System (Waters ACQUITY UPLC

(Waters Co., Ltd. Milford, Mass., USA), a column (Waters ACQUITY UPLC BEH C (TM)

, 1.7 (2.1 mm ID x 100 mm L)), a centrifuge (micro-centrifuge 1-14, Sartorius, German), a vortex mixer (genie-2, scientific industries, (GC / MS-QP2010, Shimadzu, Japan) and Restek column (0.25 mm, 30 m; XTI-5).

(2) Experimental process

1) Setting LC / MS / MS conditions

Formic acid in DW (buffer A) and 0.1% formic acid in acetronitrile (buffer B) d were used as the mobile phase. The flow rate was 0.3 ml / min Respectively.

The UPLC column was ACQUITY UPLC BEH C18 (2.1 X 100 mm, 1.7 탆) and the data processing device was MassLynx software version 4.1 (Waters Co. Ltd. Elstree, UK).

Peak detection was detected by triple-quadrupole mass spectrometry using multiple reaction monitoring spectrometry (MRM) and ionization was performed using a turbo ion spray (electrospray ionization ESI mode) was used.

The cone voltage was 42V each and the ion source temperature was set at 380 ° C.

In addition, the detection using the MRM mode was performed at 200 dwell time (ms). The m / z was 579.2 → 151.07, 579.2 → 271.2, and the collision energy was 42 (eV) 34 (eV).

At this time, the preprocessing process is as follows.

100 ㎕ of dermis extract was mixed with 900 Me of MeOH, sonicated, and then separated using a centrifugal separator. It was then diluted 10-fold and injected 3 times.

2) GC-MS condition setting

Analysis of GC-MS (GCMS-QP2010 Shimadzu, Kyoto, Japan) was performed using gas chromatography and mass spectrometer using ionization voltage at 70 eV.

(30 m x 0.25 mm x 0.25 μm, film thickness, J & W Scientific, CA, USA) and temperature-programming mode. The initial column temperature was raised to 10 ^° C / min for 3 min at 70 ^° C, and then maintained at 300 ^° C for 5 min.

The injection port temperature was 280 ^° C, the GC / MS interface was maintained at 290 ^° C, and the carrier gas was helium (He) injected with 1 μl injection volume.

The fragmentation pattern and the retention time of the degradation products were confirmed using a NIST spectral library of GC-MS software (version 1.10 beta Shimadzu, Kyoto, Japan).

(2) Experimental results

3 is a table showing final compound information of Naringin.

Figures 4, 5, 6, 7, 8, 9, and 10 are graphs of analytical chemical analysis of Naringin.

For the quantification of the material, a standard curve of the standard material was prepared. The correlation coefficient of the standard curve was very good linearity of R ² = 0.999 or more.

The LC / MS / MS chromatogram showed the naringin content of the dermis extract at 0.275 mg / g using four concentrations of Naringin's standard solution.

11 is a graph comparing the chromatography of caffeine contained in guarana based on chromatography of 50 ppm and 100 ppm of caffeine.

12 is a graph showing a standard curve of caffeine contained in the guarana.

As a result of GC-MS analysis, R.time 18.512 minutes, I.Time 18.465 minutes, F.Time 18.595 minutes at 50 ppm of the reference material caffeine chromatogram, 100 ppm R.time 18.510 minutes, I.Time 18.455 minutes, F.Time 18.570 minutes , And R. time 18.526 minutes, I.Time 18.465 minutes and F.Time 18.585 minutes for the water extract of Guarana.

The peak area of 43895 and 100 ppm of caffeine standard material were 43895 and 84311, respectively. The correlation coefficient R ² = 0.999 or more of the standard curve showed a very good linearity. The caffeine peak area contained in the guarana was 281920 And the caffeine content was confirmed to be 334 mg / g by GC-MS analysis.

Experimental Example  2. Weight loss efficacy experiment of dermis and guarana extract

(1) Preparing the experiment

1) Experimental animals

Five-week-old male ICR mice (Samtako Co, Gyeonggi-do, Korea) with an average body weight of 25.5 ± 0.8 g were purchased from the experimental animals. ICR mice are known to be used for experiments such as the effects of high-fat diet on serum lipids (Jang- YS. 2010). After adjusting for basic diet for 1 week, they were divided into 7 groups and tested for 7 weeks. Feed and drinking water were freely consumed.

Experimental animals were maintained at a temperature of 232 ℃, humidity of 50 ~ 60%, ventilation frequency of 10 ~ 15 times / hour and illumination of 200 ~ 300 lux. Animal experiments were carried out in accordance with the guidelines of the Wonkwang University Animal Experimental Ethics Committee.

High-fat diets (Rodent Diet with 60% kcal fat) were purchased from Central Lab (Animal lnc, Seoul, Korea), and filtered and sterilized with ultraviolet sterilizer.

2) Experimental animal experiment plan design and group composition

After 5 weeks of growth, ICR mice were fed with normal diet for one week and high fat diet induced obesity.

The effect of simvastatin, dermis extract, guarana extract, dermis, and concha complexes at different ratios was tested on blood lipids.

Seven weeks later, animals were sacrificed and weighed and weighted, blood biochemistry and kanji quality assays, organ weighing and fat cell size measurements were performed.

Experimental animals were composed of 7 groups. The experimental animals were divided into two groups.

The control group was fed normal diet (n = 7), high fat diet (n = 7) fed high fat diets, high fat diet, and positive control with simvastatin (Positive Control; n = 7).

(HFD-Ex-100: 0; n = 7), (HFD-Ex-90: 10; n = 7) and the control group (HFD-Ex-50: 50; n = 7) and (HFD-Ex-0: 100; n = 7) groups.

FIG. 13 is a table showing the dietary feeding methods of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

The estimation of the number of marine composition was based on the principle of 3R and used the minimum number that covers the statistical meaning.

Simvastatin was administered 20 mg / kg to the control group, based on the results of Yohichi K (2012).

Based on the results of Yum JY (1998) in all experimental groups, The extract compound 500 mg / kg was administered orally once a day.

Each group was divided into three groups: NC (normal group), dyslipidemic group (HFD), ST (positive control, simvastatin group), J100 (dermis and guana 100: 0), J90: G10 (dermis and guana 90:10) G50 And Galanina 50:50) and G100 (dermis and guana 0: 100).

3) Statistical processing

The results obtained in this experiment are expressed as mean standard deviation (mean SD). The statistical significance of each test group was analyzed using the Student's t-test and SPSS V. 12 for statistical comparison between the control and experimental groups and Duncan's post test was performed p <0.05 was considered statistically significant.

It is to be noted that the preparation of the experiment in all the following experimental examples was carried out by the same procedure as in Experimental Example 2.

(2) Experimental process

Weights of each group were measured at 10 am on a weekly basis using a digital meter.

(3) Experimental results

FIG. 14 is a table showing changes in body weight of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

15 is a graph comparing changes in body weight of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

As a result, the HFD group as a negative control group was significantly increased compared with the NC group, and the fat weight of the HFD group at 7 weeks was 47.3 ± 1.9, which was about 11 g higher than that of the NC group at 36.1 ± 0.9.

In the positive control group, the weight of the ST group was 38.7 ± 1.6 at the 7th week. The weight of the J100 group at week 7 was 39.9 ± 1.2, the J90 group was 39.6 ± 1.2, the J50 group was 37.3 ± 0.6, Was 40.2 ± 1.5.

In the J50: G50 group, the reduction rate was higher than that of J100 and G100, which were treated with the single extract group. In addition, the decrease in the fat weight of the control group was greater than that of the control group Respectively.

As a result, it can be concluded that the dandruff and guarana extract are fat reducing effect.

Experimental Example  3. Experiments on reducing liver weight of dermis and guarana extract

(1) Experimental process

After fasting for 16 hours, mice anesthetized with ether were overlaid and the liver of the mice was harvested and weighed. The absolute long-term and relative long-term weights of the experimental animals were calculated.

The relative weight was calculated based on the formula described in the following equation (1).

(2) Experimental results

FIG. 16 is a table comparing liver weight changes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

17 is a graph comparing the absolute liver weight changes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

18 is a graph comparing relative liver weight changes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

Absolute weight and relative weight of the liver extracted from mice were converted per 100 g body weight to minimize differences due to differences in body weight.

As a result, the negative control group HFD increased significantly compared to the NC group. The absolute weight of the HFD group was 1.53 ± 0.08, the relative weight was 3.24 ± 0.05, and 1.09 ± 0.06 and 3.01 ± 0.11 , And 0.2g, respectively.

Positive control ST group had an absolute weight of 1.19 ± 0.06 and a relative weight of 3.07 ± 0.04.

The absolute weight of the J100 group was 1.25 ± 0.09, the relative weight was 3.14 ± 0.16, the absolute weight of the J90: G10 group was 1.19 ± 0.05 and the relative weight was 2.99 ± 0.05. The absolute weight of the J50: G50 group was 1.1 ± 0.06, relative weight of 2.96 ± 0.13, the absolute liver weight of G100 group was 1.3 ± 0.02, and the relative weight was 3.23 ± 0.08.

The J90: G10 group and the J50: G50 group showed a higher reduction rate than the J100 and G100 groups, which were treated with the single extract group, Than the control group.

As a result, it can be concluded that the dermis and guarana extract have hepatic weight reduction efficacy.

Experimental Example  4. Experiment of reducing fat weight of dermis and guarana extract

(1) Experimental process

The mice were fasted for 16 hours and then anesthetized with ether. The epididymal fat, retroperitoneal fat and peri-renal fat were weighed and weighed. The absolute long term weight and the relative long term weight of the experimental animals were calculated based on the same formula as in Equation (1) described in Experimental Example 2.

(2) Experimental results

FIG. 19 is a table comparing the weight changes of epididymal fat, peritoneal fat, and peripheral renal fat of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

20 is a graph comparing changes in the weight of the peritoneal fat of the NC group, the HFD group, the ST group, the J100 group, the J90: G10 group, the J50: J50 group, and the G100 group.

FIG. 21 is a graph comparing changes in epididymal fat weight among NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

22 is a graph comparing the changes in the peripheral fat weight of the NC group, the HFD group, the ST group, the J100 group, the J90: G10 group, the J50: J50 group, and the G100 group.

In the HFD group, negative control group, HFD group had 0.21 ± 0.06 epididymal fat weight, 0.55 ± 0.06 peritoneal fat weight, and 2.44 ± 0.52 fat area per kidney. 0.11 ± 0.05, 0.28 ± 0.05, and 0.84 ± 0.14, respectively.

In the ST group, the epididymal fat weight was 0.11 ± 0.05, the peritoneal fat weight was 0.38 ± 0.02, and the peripheral fat weight was 1.19 ± 0.25.

In the J100 group, epididymal fat weight was 0.13 ± 0.02, peritoneal fat weight was 0.4 ± 0.02, and peripheral fat weight was 1.34 ± 0.41. In the J90: G10 group, epididymal fat weight was 0.12 ± 0.05, ± 0.05, and the peripheral fat weight was 1.13 ± 0.16.

 J50: The epididymal fat weight of the G50 group was 0.09 ± 0.01, the peritoneal fat weight was 0.29 ± 0.04, the peripheral fat weight was 0.91 ± 0.20, the epididymal fat weight of the G100 group was 0.15 ± 0.04, 0.05, and the fat around the kidney was 1.37 ± 0.48.

The epididymal fat mass, peritoneal fat mass, and peripheral fat weight of all experimental groups were significantly lower than those of negative control epididymal fat mass, peritoneal fat mass, and peripheral fat weight, respectively. Especially, J90: G10 group and J50: In the G50 group, the reduction rate was higher than that of the J100 group and G100 group, which were treated with the single extract group, and the reduction rate was larger than that of the ST group.

Thus, it can be concluded that the dermis and guarana extract are effective in reducing epididymal fat weight, post-peritoneal fat weight, and perineural fat weight.

Experimental Example  5. Experiments to inhibit hepatic injury of dermis and guarana extract (1)

(1) Experimental process

Mice were fasted for 16 hours and anesthetized with ether. After the laparotomy, blood was collected from the abdominal vena cava and the blood was centrifuged at 3,000 rpm for 15 minutes to separate the serum.

The activity of GOT (Glutamate oxaloacetate transminase) and GPT (Serum glutamate pyruvate transminase), which are indicators of hepatic damage inhibition, was measured using an automatic biochemical tester BS-220 (Mindray, Shenzhen, Korea) using a dedicated kit (Asan Pharmaceutical Co. LTD, Jeonju, Korea) China).

(2) Experimental results

23 is a table comparing GOT and GPT of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

24 is a table comparing the GOT of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

25 is a table comparing the GPT of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

Plasma GOT and GPT activity are indicators of liver function, which is useful for screening potential liver disorders, monitoring progression of chronic diseases, and diagnosing recurrences. In other words, GOT and GPT activities are increased when liver damage is caused by internal or external factors (Ronald et al al ., 1992). However, even if liver cells are damaged by high-fat diet, alcohol, etc., GOT and GPT release into the blood are enhanced, resulting in increased enzyme activity.

As a result, the HFD group as a negative control group was significantly increased compared with the NC group, and the GOT of the liver of the HFD group was 271.6 ± 14.57 and the GPT was 69 ± 4.3, which was about 90 units / L And 25 units / L, respectively.

In the ST group, GOT was 193.8 ± 8.64 and GPT was 51.4 ± 3.44 in the positive control group.

The GOT of the J100 group was 219.4 ± 8.62 and the GPT was 57.8 ± 4.32. The GOT of the J90: G10 group was 218.8 ± 14.08 and the GPT was 56.2 ± 7.29.

The GOT of the J50 group was 197 ± 7.18 and the GPT was 50 ± 2.55. The GOT of the G100 group was 224.2 ± 7.63 and the GPT was 58.4 ± 4.72.

G90 and GPT of all experimental groups were significantly lower than those of negative control group. J90: G10 and J50: G50 groups were more decreased than J100 and G100 groups. In particular, the J50: G50 group showed a larger reduction rate than the ST group.

As a result, it can be concluded that the dermis and guarana extract have hepatic injury inhibitory effect.

Experimental Example  6. Test for reducing neutral lipid and total cholesterol content of dermis and guarana extract

(1) Experimental process

The mice used in the experiment were fasted for 16 hours, then anesthetized with ether and lyophilized. Blood was drawn from the abdominal vena cava after laparotomy and serum was separated by centrifugation at 3,000 rpm for 15 minutes.

The contents of triglyceride (TG) and total cholesterol (TC), which are major metabolites of serum lipid components, were measured by using an automatic biochemical tester BS- 220 (Mindray, Shenzhen, China).

(2) Experimental results

26 is a table comparing triglyceride content and total cholesterol content of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

27 is a graph comparing triglyceride contents of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

28 is a graph comparing the total cholesterol contents of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

As a result, the HFD group as a negative control group was significantly increased compared with the NC group, and the triglyceride content of the HFD group was 80.6 ± 6.47, the total cholesterol content was 246.4 ± 15.36, and the NC group had 37.8 ± 6.5 and 171.4 ± 16.1 mg / dl and 25 mg / dl, respectively.

In the ST group, which was a positive control, the triglyceride content was 45.4 ± 3.65 and the total cholesterol content was 196.4 ± 10.53.

The triglyceride content of the J100 group was 61.4 ± 3.44 and the total cholesterol content was 218.4 ± 11.13. The triglyceride content of the J90: G10 group was 271.6 ± 14.57 and the total cholesterol content was 56.2 ± 7.29.

The triglyceride content of J50: G50 group was 45.8 ± 4.55, the total cholesterol content was 199.2 ± 4.55, the triglyceride content of G100 group was 67.2 ± 4.97 and the total cholesterol content was 233 ± 9.82.

The triglyceride content and total cholesterol content of all experimental groups were significantly lower than those of the negative control group and triglyceride content and total cholesterol content. The J90: G10 and J50: G50 groups showed lower decrease rate than the J100 group and G100 group, Respectively.

As a result, it can be concluded that the dermis and guarana extract have a neutral lipid and total cholesterol-reducing effect.

Experimental Example  7. Dermis and Guarana extract HDL  Increased cholesterol and LDL  Cholesterol reduction efficacy experiment

(1) Experimental process

The mice used in the experiment were fasted for 16 hours, then anesthetized with ether and lyophilized. After laparotomy, blood was drawn from the abdominal vena cava and serum was separated by centrifugation at 3,000 rpm for 15 minutes.

The contents of high density lipoprotein cholesterol (HDL) and low density lipoprotein cholesterol (LDL) were measured using a special kit (Asan Pharmaceutical Co. LTD, Jeonju, Korea) as a metabolite, (Mindray, Shenzhen, China) using an automated biochemical tester BS-220.

(2) Experimental results

29 is a table comparing the HDL cholesterol and LDL cholesterol contents of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

30 is a graph comparing the HDL cholesterol contents of the NC group, the HFD group, the ST group, the J100 group, the J90: G10 group, the J50: J50 group, and the G100 group.

31 is a graph comparing the LDL cholesterol contents of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

As a result, the HFD group as a negative control group was significantly increased compared with the NC group, and the HDL cholesterol content of the HFD group was 108.2 ± 5.26, which was about 4 mg / dl lower than that of the NC group of 104.8 ± 5.26.

The HDL cholesterol content of the ST group, which was a positive control, was 135.2 ± 4.44.

The HDL cholesterol content of the J100 group was 120 ± 2.92 and the HDL cholesterol content of the J90: G10 group was 123.6 ± 4.93.

The HDL cholesterol content of the J50: G50 group was 134.2 ± 4.44, and the LDL cholesterol content of the G100 group was 115.2 ± 8.35.

HDL - cholesterol contents of all experimental groups were significantly higher than those of negative control group. J90: G10 and J50: G50 groups were higher than J100 and G100 groups.

On the other hand, the HFD group as a negative control group was significantly increased compared with the NC group, and the LDL cholesterol content of the HFD group was 122.08 ± 18.4, which was about 63 mg / dl higher than that of the NC group of 59.04 ± 17.79.

The LDL cholesterol content of the ST group, a positive control group, was 52.12 ± 12.48.

The LDL cholesterol content of the J100 group was 86.12 ± 10.43 and the LDL cholesterol content of the J90: G10 group was 74.92 ± 12.29.

The LD50 cholesterol content of the J50: G50 group was 55.84 ± 7.76 and the LDL cholesterol content of the G100 group was 104.36 ± 11.08.

The LDL cholesterol content of all experimental groups was significantly lower than that of the negative control group. The J90: G10 and J50: G50 groups had a higher rate of decrease than the J100 and G100 groups, which were administered alone.

This can lead to the conclusion that the dermis and guarana extract are effective in increasing HDL cholesterol and reducing LDL cholesterol.

Experimental Example  8. Effect of dermis and guarana extract on atherosclerosis index

(1) Experimental process

The atherogenic index was calculated using the measured total cholesterol and HDL cholesterol contents.

The arteriosclerosis index was calculated based on the formula described in the following equation (2).

(2) Experimental results

32 is a table comparing the atherogenic indexes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

33 is a graph comparing the atherogenic indexes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

Atherosclerosis index was used as a risk signal for atherosclerosis when the value in the clinic was more than 3.0, representing a concentration of triglyceride for HDL-cholesterol in the body (Rosenfeld L, 1989).

As a result, the HFD group as a negative control group was significantly increased compared with the NC group. The atherogenic index of the HFD group was 1.28 ± 0.20, which was 0.64 ± 0.1% higher than that of the NC group.

The atherosclerotic index of the ST group was 0.45 ± 0.10 in the positive control group, 0.82 ± 0.09 in the J100 group, 0.70 ± 0.11 in the J90 group, 0.49 ± 0.07 in the G50 group, and 1.03 ± 0.14 in the G100 group Respectively.

The atherogenic indexes of all experimental groups were significantly lower than those of the negative controls. J90: G10 and J50: G50 groups had a lower rate of decrease than those of J100 and G100 groups.

Thus, it can be concluded that the dermis and guarana extract have the effect of decreasing the arteriosclerosis index.

Experimental Example  9. Experiments to reduce the cardiovascular risk index of dermis and guarana extract

(1) Experimental process

The cardiac risk factor was calculated using the measured total cholesterol and HDL cholesterol levels.

The cardiac risk index was calculated based on the formula described in the following equation (3).

(2) Experimental results

34 is a chart comparing the cardiac risk indexes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

35 is a graph comparing cardiac risk indexes of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

As a result, the HFD group as a negative control group was significantly increased compared with the NC group. The cardiac risk index of the HFD group was 2.28 ± 0.2, which was about 0.64% higher than that of NC group 1.64 ± 0.19.

The cardiac risk index of the ST group was 1.45 ± 0.1, the cardiac risk index of the J100 group was 1.82 ± 0.09, the J90 group was 1.7 ± 0.11, the J50 group was 1.49 ± 0.07, and the G100 group was 2.03 ± 0.14 Respectively.

The cardiac risk index of all experimental groups was significantly lower than that of the negative control group. J90: G10 and J50: G50 groups had a higher rate of decrease than those of J100 group and G100 group.

This can lead to the conclusion that the dermis and guarana extracts have cardiovascular risk index reduction efficacy.

Experimental Example  10. Experiment of blood sugar reduction effect of dermis and guarana extract

(1) Experimental process

The mice were fasted for 16 hours, anesthetized with ether and lavaged. After laparotomy, blood was drawn from the abdominal vena cava and serum was separated by centrifugation at 3,000 rpm for 15 minutes.

The glucose content of the plasma was measured with an automatic biochemical test machine BS-220 (Mindray, Shenzhen, China) using a dedicated kit (Asan Pharmaceutical Co. LTD, Jeonju, Korea) as a metabolite which is a main index of blood lipid.

(2) Experimental results

FIG. 36 is a table comparing the blood glucose levels of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

37 is a graph comparing blood glucose levels of the NC group, the HFD group, the ST group, the J100 group, the J90: G10 group, the J50: J50 group, and the G100 group.

Blood sugar is influenced by the degradation and glycosylation of glycogen in the sugar and liver that are absorbed into the blood and removed from the incoming sugar and blood from each tissue. Obesity and diabetes mellitus have been reported to cause glucose intolerance due to the inability of the liver to suppress the release of glucose from the liver, rather than to decrease the glucose removal function in the blood after the glucose is introduced into the body.

As a result, the HFD group as a negative control group was significantly increased compared with the NC group, and the blood glucose level of the HFD group was 148.2 ± 10.73, which was about 82 mg / dl higher than that of the NC group of 66.2 ± 7.53.

The blood glucose level of the ST group was 105 ± 5.1. The blood glucose level of the J100 group was 128.6 ± 9.63, that of the J90 group was 126.8 ± 12.03, that of the J50 group was 104.8 ± 7.33, and that of the G100 group was 127.4 ± 9.56.

The blood glucose levels of all experimental groups were significantly lower than those of the negative control group. J90: G10 and J50: G50 groups had a lower rate of decrease than the J100 and G100 groups. In particular, the J50: G50 group showed a higher reduction rate than the ST group.

As a result, it can be concluded that the dermis and guarana extract have a hypoglycemic effect.

Experimental Example  11. Experiments to inhibit hepatic injury of dermis and guarana extract (2)

(1) Experimental process

The mice were fasted for 16 hours, anesthetized with ether and lavaged. After removal of the liver, the liver was washed with physiological saline, and water was removed with a filter paper, and a part of the liver tissue was fixed in 10% neutral formalin.

Subsequently, a part of the liver tissue was embedded in paraffin using a method for histopathological examination, and then sliced into a thickness of 4 μm, and then slides were prepared and stained with H & E (Hematoxyline & Eosin).

The NASH (nonalcoholic steatohepatitis) score was measured at a magnification of 100 times under an optical microscope of Nikon Eclipse E200 (Nikon, Tokyo, Japan). NASH is a nonalcoholic fatty hepatitis characterized by the presence of three lesions, mainly giant hydronephrosis, hepatocyte injury, and mixed inflammation, distributed in three areas and central lobes.

The NASH score was calculated by comparing the score of the degree of lipemia, balloon degeneration, and lobar inflammation on the H & E stained slides using an optical microscope.

(2) Experimental results

FIG. 38 is a table comparing NASH of NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

FIG. 39 is a photograph showing anatomical comparison of the progression of NASH in NC group, HFD group, ST group, and J100 group.

40 is a photograph showing anatomical comparison of NASH progress of J90: G10 group, J50: J50 group, and G100 group.

Observation of liver tissue by H & E staining with optical microscope revealed no evidence of fat accumulation in the NC group (steatosis grade, lobular inflammation, hepatocellular ballooning) The balloons were not observed, and the hepatic cells showed clearly the shape of the nucleus and the cell gap was constant.

In ST group, hepatocytes constituting hepatic lobules were uniformly arranged on the whole.

In addition, J100, J90: G10 and G100 groups showed a slight tendency of fat accumulation, inflammation and ballooning, whereas J50: G50 group showed that many fat cells were uniformly arranged throughout liver tissue, Was observed.

As a result, it can be concluded that the dermis and guarana extract have the effect of inhibiting liver damage.

Experimental Example  12. Experiments on fat cell size reduction effect of dermis and guarana extract

(1) Experimental process

Mice were fasted for 16 hours, anesthetized with ether, and then lavaged to obtain epididymal fat, retroperitoneal fat, and peri-renal fat. Were measured.

(2) Experimental results

41 is a table comparing the epididymal fat and peritoneal fat masses of the NC group, HFD group, ST group, J100 group, J90: G10 group, J50: J50 group and G100 group.

Fig. 42 is a photograph showing anatomical comparison of epididymal fat sizes of NC group (A), HFD group (B), ST group (C) and J100 group (D).

FIG. 43 is a photograph showing an epidemiological comparison of epididymal fat sizes of J90: G10 (E), J50: J50 (F) and G100 (G) groups.

FIG. 44 is a photograph showing the anatomical comparison of the peritoneal fat masses of the NC group (A), the HFD group (B), the ST group (C), and the J100 group (D).

FIG. 45 is a photograph showing the anatomical comparison of the peritoneal fat masses of J90: G10 (E), J50: J50 (F) and G100 (G) groups.

In the epididymal region, the lipid size was significantly decreased in all groups except the HFD group, and a significant decrease was observed in the complex J50: G50 group compared with the single extract group.

There was a significant decrease in lipid size in all groups except the HFD group and a significant decrease in the complex J50: G50 group compared with the single extract group.

With this, it can be concluded that the dermis and guarana extract are effective in reducing fat cell size.

Claims (6)

A composition comprising 100 parts by weight of a guarana extract and 100 to 900 parts by weight of a dermis extract as an active ingredient, wherein the complex is administered orally 450 to 550 mg / kg once a day on a 5-week-old mouse basis , A composition for preventing, ameliorating or treating metabolic syndrome.
The method according to claim 1,
The complex is effective for reducing body weight, reducing liver weight, reducing fat weight, inhibiting liver damage, reducing triglyceride and total cholesterol, increasing HDL cholesterol and decreasing LDL cholesterol Efficacy to reduce atherosclerosis index, efficacy to reduce cardiac risk index, efficacy to reduce blood sugar, efficacy to reduce liver fat accumulation, efficacy to reduce liver inflammation, efficacy to reduce liver balloon count And metabolic syndrome including diabetes mellitus, obesity, diabetes mellitus, atherosclerosis, hypertension, and fatty liver by having the effect of reducing the size of fat cells.
delete delete A pharmaceutical preparation containing a pharmaceutically acceptable additive added to a composition for treating the metabolic syndrome according to claim 1 or 2.
A health functional food comprising a composition for preventing or ameliorating the metabolic syndrome according to claim 1 or 2, wherein a pharmaceutically acceptable additive is added.

Images